(NASDAQ: AVXL) Anavex Life Sciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Anavex Life Sciences's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast AVXL's revenue for 2024 to be $2,314,751,685, with the lowest AVXL revenue forecast at $2,314,751,685, and the highest AVXL revenue forecast at $2,314,751,685. On average, 1 Wall Street analysts forecast AVXL's revenue for 2025 to be $3,541,512,599, with the lowest AVXL revenue forecast at $3,541,512,599, and the highest AVXL revenue forecast at $3,541,512,599.
In 2026, AVXL is forecast to generate $147,625,977,901 in revenue, with the lowest revenue forecast at $147,625,977,901 and the highest revenue forecast at $147,625,977,901.